

MSE Integrated Care Partnership, 16 November 2022

Agenda Number: 09

MSE ICS Integrated Weight Management Services Redesign

Summary Report

1. Purpose of Report

To provide the Integrated Care Partnership with an overview of one of the innovative ways of working with industry, specifically with a pharmaceutical company to redesign MSE Integrated weight management services.

2. Executive Lead

- Name: **Jeff Banks**
- Job Title: **Director of Strategy and Partnerships**

3. Report Author

- Name: **Emma Timpson and Dr Peter Scolding**
- Job Title: **Associate Director Health Inequalities (ICB) and Prevention and Assistant Medical Director (ICB)**

4. Responsible Committees

The ICB Executive Directors meet on 7 November 2022 and approved proceeding with the Collaborative partnership with a pharmaceutical company to redesign MSE Integrated weight management services.

5. Financial Implications

The pharmaceutical company will provide a financial contribution of £206,000 over a period of 2 years to support the recruitment of a project manager and support officer and the facilitation of workshops. There is no financial implication to the ICB.

6. Details of patient or public engagement or consultation

The development of the collaborative partnership has been overseen by the Weight Management Services Programme Board that has representation from the ICB prevention teams, Alliances and the three Local Authorities public health and wellbeing teams.

7. Conflicts of Interest

The collaborative partnership with the pharmaceutical company will be conducted through an open and transparent process. Conflicts of interest will be managed in accordance with the ICB Conflicts of Interest Policy. In addition the collaborative partnership will operate in accordance with the Association of the British

Pharmaceutical Industry (ABPI) guidelines. Clinical and prescribing policies and guidelines will always be based upon the principles of evidence-based medicine and cost effectiveness and reflect recommendations from expert bodies specifically the National Institute for Health Care and Excellence.

8. Recommendation/s

The Integrated Care Partnership is asked to support the innovative collaborative partnership with a pharmaceutical company to redesign Weight Management Services.

MSE ICS Integrated Weight Management Services Redesign

1. Introduction

As an Integrated Care System, we need to move upstream, from a focus on treatment towards prevention. Adopting a partnership approach across local authorities, health, communities and with industry will enable us to identify innovative solutions that support the development of sustainable health lifestyles and behaviours to reduce health inequalities.

Obesity is one of the biggest risk factors for individual's health and is a leading cause of preventable illness and premature death nationally. Almost two-thirds of adults in Mid and South Essex are living with excess weight or obesity. Evidence suggests weight management services can help people to adopt healthier behaviours, lose weight and improve their general wellbeing.

The transformation of weight management services across Mid and South Essex is therefore a priority for the Prevention programme. The ambition is to integrated care to ensure people across Essex get access to an appropriately personalised weight management service at the right time, with demonstrable outcomes.

Collaborative working with industry can deliver significant benefits to our residents and patients by sharing of knowledge and expertise around the common agenda of improving patient care outcomes through high quality and cost effective treatment and management.

2. Main content of Report

As part of this innovative approach, Mid and South Essex ICS are looking to embark on a collaborative partnership with a pharmaceutical corporation to pool skills, expertise, and gain financial backing for this project.

The pharmaceutical company and MSE ICS will combine financial and non-financial resources to redesign the weight management pathway in Mid and South Essex. MSE ICS will provide clinical and non-clinical resource and training. The pharmaceutical company will provide financial support of £206,000 to fund two dedicated roles within the MSE ICS weight management team and provide facilitation support over a two-year period.

From the pharmaceutical company's perspective, by supporting the development of one of the first integrated and innovative weight management service transformations in England, they will benefit through gaining a richer understanding of patient and customer needs, how weight management services may develop across England, and the challenges involved, which may inform future collaborations and service offerings. Service delivery will remain in line with local formulary and NICE guidelines.

An MSE ICS steering group will meet monthly to review and track progress. There will be representation on the group from the three Local Authorities alongside the ICB Prevention team, finance, contracting and procurement leads. Other stakeholders will join the steering group or operational groups as needed including patient representatives and community providers.

The work will be conducted in two phases:

Phase 1

- System-wide approach to deliver optimized Tier 2 and Tier 3 Weight Management Pathway for Adults including access to NICE-mandated treatments, within existing commissioning framework
- Education and training on referral pathways for referrers across MSE

Phase 2

- A more personalised, integrated WMS pathway within a Stewardship framework (i.e. clarity on resource use and value delivered for individuals and population, an integrated, whole-pathway, whole-population approach developed and delivered collaboratively) by December 2024

In working with the Pharmaceutical partner, the principles of transparency will be applied and ensuring patient care is enhanced. There is a formal written collaborative agreement that sets out the ways of working including financial risk sharing, publishing of outcomes, intellectual property and exit criteria. The MSE ICB Executive team have reviewed and approved the collaborative agreement.

To comply with the ABPI code of practice a summary of the Collaborative Working Agreement will be published in advance of commencement of the project on the pharmaceutical company and MSE ICS websites.

3. Findings/Conclusion

This project offers an excellent and early opportunity to work collaboratively with industry, sharing financial, information and expertise resources and spearheading the much-needed transformation of weight management services across MSE, simultaneously setting a benchmarking example which can be shared with other ICSs across the country.

4. Recommendation(s)

The Integrated Care Partnership is asked to support the innovative collaborative partnership with a pharmaceutical company to redesign Weight Management Services.